Blue Earth Therapeutics Ltd United Kingdom

(177Lu) rhPSMA-10.1 injection, engineered to improve delivery of radiation to cancer lesions, recently showed promising data in a phase 1 trial1The goal of the phase 2 study is to further assess this improved profile, together with testing of optimised dosing regimensFirst patients have received doses of (177Lu) rhPSMA-10.1 injection1st study results could be available as soon as H1 2026View original content:https://www.prnewswire.co.uk/news-releases/blue-earth-therapeutics-initiates-phase-2-clinical-trial-evaluating-the-efficacy-and-safety-of-lutetium-177lu-rhpsma-10-1-injection-in-metastatic-castrate-resistant-prostate-cancer-302441702.html